Column: Comparative-research provision draws major criticism

02/12/2009 | Washington Post (tiered subscription model), The

The $1.1 billion fund allocated for comparative-effectiveness research in the economic-stimulus package has drawn criticism from some health experts and media members who say the move ultimately will allow the government to dictate what medicines people should or should not receive, writes Washington Post columnist Steven Pearlstein. Although this is unlikely if the research is carried out in a "disciplined, scientific way," the concerns should serve to warn the Obama administration of how health care reform likely will become a "vicious and divisive" issue, Pearlstein writes.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ